Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States
- 19 November 2009
- journal article
- research article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 29 (6) , 647-653
- https://doi.org/10.1016/j.urolonc.2009.09.004
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- The Role of Primary Androgen Deprivation Therapy in Localized Prostate CancerEuropean Urology, 2009
- Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancerBMC Health Services Research, 2008
- Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate CancerJAMA, 2008
- Characteristics of Urologists Predict the Use of Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2007
- Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and TreatmentJournal of Urology, 2007
- IntroductionAmerican Journal of Health-System Pharmacy, 2006
- The rising prevalence of androgen deprivation among older American men since the advent of prostate‐specific antigen testing: a population‐based cohort studyBJU International, 2006
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Determinants of Androgen Deprivation Therapy Use for Prostate Cancer: Role of the UrologistJNCI Journal of the National Cancer Institute, 2006
- Increasing use of gonadotropin‐releasing hormone agonists for the treatment of localized prostate carcinomaCancer, 2005